Chinese biotech PegBio’s shares fall 13% on Hong Kong IPO debut

A core product for Type 2 diabetes is expected to commercially launch in mainland China by the end of this year, subject to regulatory approval; CICC led the transaction.

Ryan Li

May 27, 2025

PegBio, a Hangzhou-headquartered Chinese biotech firm, made its debut on the main board of the Hong Kong Stock Exchange (HKEX) on May 27. The stock opened at HK$13.5 ($1.7) per share, 13.5% lower than the listing price of HK$15.6, which placed the initial public offering (IPO) offer at HK$300.8 million in total size.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.